Cargando…

Low Molecular Weight Chitosan-Coated PLGA Nanoparticles for Pulmonary Delivery of Tobramycin for Cystic Fibrosis

(1) Background: Poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) loaded with Tobramycin were prepared using a solvent-evaporation method. (2) Methods: The NPs were coated with low molecular weight chitosan (LMWC) to enhance the mucoadhesiveness of PLGA-NPs. The following w/w ratios of tobram...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Nemrawi, Nusaiba K., Alshraiedeh, Nid’’A H., Zayed, Aref L., Altaani, Bashar M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874724/ https://www.ncbi.nlm.nih.gov/pubmed/29517998 http://dx.doi.org/10.3390/ph11010028

Ejemplares similares

Formulation and characterization of tobramycin-chitosan nanoparticles coated with zinc oxide nanoparticles
por: Al-nemrawi, Nusaiba.K., et al.
Publicado: (2022)

A novel formulation of chitosan nanoparticles functionalized with titanium dioxide nanoparticles
por: Al-Nemrawi, Nusaiba, et al.
Publicado: (2021)

Identification and characterization of bacteria isolated from patients with cystic fibrosis in Jordan
por: Alshraiedeh, Nid’a, et al.
Publicado: (2022)

Photolytic Controlled Release Formulation of Methotrexate Loaded in Chitosan/TiO(2) Nanoparticles for Breast Cancer
por: Al-Nemrawi, Nusaiba, et al.
Publicado: (2022)

Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis
por: Vendrell, Montserrat, et al.
Publicado: (2015)

Chitosan Oleate Coated PLGA Nanoparticles as siRNA Drug Delivery System
por: Miele, Dalila, et al.
Publicado: (2021)

Formulation of Antimicrobial Tobramycin Loaded PLGA Nanoparticles via Complexation with AOT
por: Hill, Marcus, et al.
Publicado: (2019)

Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014)

Long-term safety and efficacy of tobramycin in the management of cystic fibrosis
por: Vázquez-Espinosa, Emma, et al.
Publicado: (2015)

Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis
por: Vij, Neeraj, et al.
Publicado: (2010)

Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review
por: VanDevanter, Donald R, et al.
Publicado: (2011)

Azithromycin and Tobramycin Therapy in Cystic Fibrosis Pulmonary Exacerbations: Less Is More?
por: Thornton, Christina, et al.
Publicado: (2021)

Tobramycin-loaded nanoparticles of thiolated chitosan for ocular drug delivery: Preparation, mucoadhesion and pharmacokinetic evaluation
por: Javed, Sadaf, et al.
Publicado: (2023)

Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder
por: Greenberg, Jonathan, et al.
Publicado: (2016)

Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2020)

Implementation of Model-Based Dose Adjustment of Tobramycin in Adult Patients with Cystic Fibrosis
por: Reverchon, Jérémy, et al.
Publicado: (2022)

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
por: Uttley, Lesley, et al.
Publicado: (2013)

Chitosan-Coated Nanoparticles: Effect of Chitosan Molecular Weight on Nasal Transmucosal Delivery
por: Bruinsmann, Franciele Aline, et al.
Publicado: (2019)

Chitosan-Modified PLGA Nanoparticles for Control-Released Drug Delivery
por: Lu, Boting, et al.
Publicado: (2019)

Chitosan-Coated PLGA Nanoparticles Encapsulating Triamcinolone Acetonide as a Potential Candidate for Sustained Ocular Drug Delivery
por: Dandamudi, Madhuri, et al.
Publicado: (2021)

Tobramycin and Amikacin Delay Adhesion and Microcolony Formation in Pseudomonas aeruginosa Cystic Fibrosis Isolates
por: Olivares, Elodie, et al.
Publicado: (2017)

Association of Indocyanine Green with Chitosan Oleate Coated PLGA Nanoparticles for Photodynamic Therapy
por: Miele, Dalila, et al.
Publicado: (2022)

Development and evaluation of Desvenlafaxine loaded PLGA-chitosan nanoparticles for brain delivery
por: Tong, Gui-Feng, et al.
Publicado: (2017)

Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis
por: Deschamp, Ashley R, et al.
Publicado: (2017)

Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough
por: Meerburg, Jennifer J., et al.
Publicado: (2019)

Is it Worth Adding Systemic Antibiotics to Inhalational Tobramycin Therapy to Treat Pseudomonas Infections in Cystic Fibrosis?
por: Karki, Kumar, et al.
Publicado: (2021)

Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection
por: Greenwood, James, et al.
Publicado: (2017)

Chitosan-Coated PLGA Nanoparticles for Enhanced Ocular Anti-Inflammatory Efficacy of Atorvastatin Calcium
por: Arafa, Mona G, et al.
Publicado: (2020)

Gefitinib loaded PLGA and chitosan coated PLGA nanoparticles with magnified cytotoxicity against A549 lung cancer cell lines
por: Alshetaili, Abdullah S.
Publicado: (2021)

Once daily aerosolised tobramycin in adult patients with cystic fibrosis in the management of Pseudomonas aeruginosa chronic infection
por: Mantero, Marco, et al.
Publicado: (2017)

Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients
por: Stehling, Florian, et al.
Publicado: (2017)

Evaluation of the Risk for Acute Kidney Injury in Adult Cystic Fibrosis Patients Receiving Concomitant Vancomycin and Tobramycin
por: Muirhead, Corinne, et al.
Publicado: (2017)

Novel glycopolymer sensitizes Burkholderia cepacia complex isolates from cystic fibrosis patients to tobramycin and meropenem
por: Narayanaswamy, Vidya P., et al.
Publicado: (2017)

Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa
por: Murphy, Ronan A., et al.
Publicado: (2022)

Eradication of Burkholderia cepacia complex in cystic fibrosis patients with inhalation of amiloride and tobramycin combined with oral cotrimoxazole
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2023)

Chemodrug delivery using integrin-targeted PLGA-Chitosan nanoparticle for lung cancer therapy
por: Babu, Anish, et al.
Publicado: (2017)

Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis
por: Lam, John, et al.
Publicado: (2013)

Clinical impact of laboratory error on therapeutic drug monitoring of once-daily tobramycin in cystic fibrosis: Case series
por: Prescott, William A, et al.
Publicado: (2014)

Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients
por: Hoppentocht, Marcel, et al.
Publicado: (2016)

Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation
por: Price, Katherine E., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tg6mjvds2on0t7rasaehih908r